题名

新型冠狀病毒肺炎中醫瘟疫試治

并列篇名

Potential Treatment for New Coronavirus Pneumonia by Traditional Chinese Medicine

DOI

10.7102/JTCIM.202012_18(2).0002

作者

許詠棠(Yung-Tang Hsu)；蔡金川(Chin-Chuan Tsai)；洪裕強(Yu-Chiang Hung)

关键词

冠狀病毒 ； 肺炎 ； 中醫藥 ； Coronavirus ； Pneumonia ； Chinese medicine

期刊名称

中醫內科醫學雜誌

卷期/出版年月

18卷2期（2020 / 12 / 01）

页次

12 - 34

内容语文

繁體中文
中文摘要

從2019年12月31日武漢市衛健委公告27例肺炎後，疫情不斷延燒，世界衛生組織（WHO）在2020年1月31日史上第6度宣告新型冠狀病毒肺炎已經構成「國際關注公共衛生緊急事件」。近期疫情已擴散至全球，除中國以外，擴散至美國、巴西、印度、俄羅斯、秘魯、南非、英國、法國、義大利、伊朗、等國最為嚴重，大部分的患者會有發燒、乾咳、倦怠的症狀，約有1／3的患者會有呼吸急促的狀況，其他較少的症狀包含失去味覺或嗅覺、肌肉痛、喉嚨痛、腹瀉等，另外需特別注意，有20%～30%的感染患者是僅有輕微症狀或無症狀的。目前還沒有針對該病毒的特效藥，臨床普遍採用幫病人提高免疫力，維持機體功能的治療方式，疫苗研發也正如火如荼的進行中。新型冠狀病毒肺炎屬於中醫疫病範疇，因感受疫戾之氣所造成，也可以由五運六氣的方式解釋之，其實，中醫藥從古至今對於瘟疫的論治百花齊放，從張仲景傷寒論的麻杏甘石湯，楊栗山傷寒溫疫條辨的升降散，余師愚疫疹一得的清瘟敗毒飲，到瘟疫論大家吳又可的達原飲等，在在顯示中醫在治療戾氣上的專精，中國連花清瘟飲【連翹、金銀花、麻黃、苦杏仁、石膏、板藍根等藥物】在COVID-19的治療也有一些效果。中醫以三陰三陽、衛氣營血、三焦辨證等系統認識和治療外感病，透過調整自身陰陽氣血以正氣抗邪，中藥可能是治療新型冠狀病毒肺炎的另一種選擇。
英文摘要

Since the announcement of 27 cases of 2019-nCov by Wuhan Municipal Health Commission on December 31, 2019, the epidemic has spread all over the world. On January 30, 2020, the World Health Organization also declared the coronavirus outbreak an ＂public health emergency of international concern Global Public Health Emergency＂ for the sixth time in the history. Apart from China, the epidemic is most severe in the United States, Brazil, India, Britain, France, Italy, Iran, Russia, and Peru. Most patients have symptoms of fever, dry cough, and burnout. About one-third of patients have shortness of breath, and other less symptoms include loss of taste or smell, muscle pain, sore throat, diarrhea, and etc. In addition, 20% to 30% of infected patients have only mild symptoms or no symptom. At present, there is no specific medicine for the virus, and the clinical treatment is mainly supportive therapy. Vaccine development is also in full swing. In terms of traditional Chinese medicine, this disease belongs to the epidemic infectious diseases of Chinese medicine. As a result of feeling the epidemic qi, it can also be explained by Chinese medicine theory of the five movements and six qi. Actually, traditional Chinese medicine already had different kinds of the treatments of plague since ancient times. For example, Ma-Xing-Gan-Shi-Tang from the typhoid theory written by Zhang, Zhong-Jing, Sheng-jiang powder from Shan-han-wen-bing-tiao-bian written by Yang, Li-shan, Qing-Wen-Bai-Du-Yin from Yi-zhen-yi-de written by Yu, Shih-Yu, Da-Yuan-Yin from Plague theory written by Wu, Yu-Ke are all prescriptions of chinese materia medica in showing the expertise of traditional Chinese medicine in treatment of the epidemic qi. The team of Dr. Zhong, Nan-Shan in China also had research of Lian-hua-qing-wen-yin which includes Forsythia, Honeysuckle, Ephedra, Bitter Almond, Gypsum and Indigowoad Root, played an active role in the treatment of COVID-19. In traditional Chinese medicine, the theories of ＂Threeyin and Threeyang＂, ＂Wei-QI-Ying-Xue＂ and ＂San-Jiao Pattern Differentiation＂ could have their unique ways for analysis and treatment of exogenous disease. By adjusting people's own yin qi, yang qi and blood to fight evil qi with right qi, the Chinese medicine could be another choice for the treatment of COVID-19.
主题分类 醫藥衛生 > 中醫藥學
参考文献
  1. Caly, L,Druce, JD,Catton, MG,Jans, DA,Wagstaff, KM(2020).The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res,178,104787.
  2. Cao, B,Wang, Y,Wen, D,Liu, W,Wang, J,Fan, G(2020).A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19.N Engl J Med,382,1787-1799.
  3. CDC COVID-19 Response Team(2020).Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12–March 16, 2020.MMWR,69(12),343-346.
  4. Chan, JF,Kok, KH,Zhu, Z,Chu, H,To, KK,Yuan, S,Yuen, KY(2020).Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.Emerg Microbes Infect,9(1),221-236.
  5. Chang, D,Lin, M,Wei, L,Xie, L,Zhu, G,Cruz, CSD(2020).Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China.JAMA,323(11),1092-1093.
  6. Chen, L,Xiong, J,Bao, L,Shi, Y(2020).Convalescent plasma as a potential therapy for COVID-19.Lancet Infect Dis,20(4),398-400.
  7. Cheng, Y,Wong, R,Soo, Y,Wong, W,Lee, C,Ng, M(2005).Use of convalescent plasma therapy in SARS patients in Hong Kong.Eur J Clin Microbiol Infect Dis,24(1),44-46.
  8. Chu, C,Cheng, V,Hung, I,Wong, M,Chan, K,Chan, K(2004).Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.Thorax,59(3),252-256.
  9. Dong, L,Hu, S,Gao, J(2020).Discovering drugs to treat coronavirus disease 2019 (COVID-19).Drug Discov Ther,14(1),58-60.
  10. Duan, K,Liu, B,Li, C,Zhang, H,Yu, T,Qu, J(2020).Effectiveness of convalescent plasma therapy in severe COVID-19 patients.Proc Natl Acad Sci USA,117(17),9490-9496.
  11. Elfiky, AA(2020).Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.Life Sci,248,117477.
  12. Holshue, ML,DeBolt, C,Lindquist, S,Lofy, KH,Wiesman, J,Bruce, H,Spitters, C,Ericson, K(2020).First case of 2019 novel coronavirus in the United States.N Engl J Med,382(10),929-936.
  13. Ji, W,Wang, W,Zhao, X,Zai, J,Li, X(2020).Cross‐species transmission of the newly identified coronavirus 2019‐nCoV.J Med Virol,92(4),433-440.
  14. Li, G,De Clercq, E(2020).Therapeutic options for the 2019 novel coronavirus (2019-nCoV).Nat Rev Drug Discov,19(3),149-150.
  15. Li, H,Wang, YM,Xu, JY,Cao, B(2020).Potential antiviral therapeutics for 2019 Novel Coronavirus.Zhonghua Jie He He Hu Xi Za Zhi,43(3),170-172.
  16. Lim, J,Jeon, S,Shin, H-Y,Kim, MJ,Seong, YM,Lee, WJ(2020).Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR.J Korean Med Sci,35(6),e79.
  17. Liu, L,Wei, Q,Alvarez, X,Wang, H,Du, Y,Zhu, H(2011).Epithelial cells lining salivary gland ductsare early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques.J Virol,85(8),4025-4030.
  18. MacLennan, S,Barbara, JA(2006).Risks and side effects of therapy with plasma and plasma fractions.Best Pract Res Clin Haematol,19(1),169-189.
  19. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia(2020).Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia.Zhonghua Jie He He Hu Xi Za Zhi,43(3),185-188.
  20. Organization WH. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: Interim guidance 2020;21-2. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
  21. Richardson, P,Griffin, I,Tucker, C,Smith, D,Oechsle, O,Phelan, A,Stebbing, J(2020).Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.Lancet,395(10223),e30-e31.
  22. Saglietto, A,D'Ascenzo, F,Zoccai, GB,De Ferrari, GM(2020).COVID-19 in Europe: the Italian lesson.Lancet,395(10230),1110-1111.
  23. Thorlund, K,Dron, L,Park, J,Hsu, G,Forrest, JI,Mills, EJ(2020).A real-time dashboard of clinical trials form COVID-19.Lancet Digit Health
  24. Van Griensven, J,Edwards, T,de Lamballerie, X,Semple, MG,Gallian, P,Baize, S(2016).Evaluation of convalescent plasma for Ebola virus disease in Guinea.N Engl J Med,374(1),33-42.
  25. Wang, D,Hu, B,Hu, C,Zhu, F,Liu, X,Zhang, J(2020).Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China.JAMA,323(11),1061-1069.
  26. Wang, M,Cao, R,Zhang, L,Yang, X,Liu, J,Xu, M(2020).Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.Cell Res,30(3),269-271.
  27. Wang, W,Tang, J,Wei, F(2020).Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China.J Med Virol,92(4),441-447.
  28. Weiss, SR,Navas-Martin, S(2005).Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.Microbiol Mol Biol Rev,69(4),635-664.
  29. Whitworth, J(2020).COVID-19: a fast evolving pandemic.Trans R Soc Trop Med Hyg,114(4),241-248.
  30. Zhang, Q,Wang, Y,Qi, C,Shen, L,Li, J(2020).Clinical trial analysis of 2019‐nCoV therapy registered in China.J Med Virol,92(6),540-545.
  31. Zhang, T,Wu, Q,Zhang, Z(2020).Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak.Curr Biol,30(8),1578.
  32. Zhou, P,Yang, X-L,Wang, X-G,Hu, B,Zhang, L,Zhang, W(2020).A pneumonia outbreak associated with a new coronavirus of probable bat origin.Nature,579(7798),270-273.
  33. Zumla, A,Chan, JF,Azhar, EI,Hui, DS,Yuen, KY(2016).Coronaviruses-drug discovery and therapeutic options.Nat Rev Drug Discov,15(5),327-347.
  34. 朱海峰,朱仝宣(1998)。五苓散的雙向調節作用。時珍國醫國藥，1998(6)，542。
  35. 何清湖,劉應科,孫相如,孫英凱,孫光榮(2020)。中醫藥向新型冠狀病毒肺炎亮劍—國家中醫藥管理局發布“清肺排毒湯”的意義與作用。中醫雜誌，1-4。
  36. 何黎黎,龔普陽,封玥,鄒薇,王恩龍(2020)。中藥在抗新型冠狀病毒肺炎（COVID-19）引起的細胞因子風暴中的應用分析。中草藥中藥，51(06)，1375-1385。
  37. 周銘心(2020)。從五運六氣辨識與防治新型冠狀病毒肺炎。中醫學報，35(2)，227-231。
  38. 張霆(2003)。邪伏膜原─試論傳染型非典性肺炎之病因病機及治療。天津中醫學院學報，22(3)，58-60。
  39. 張豐榮,祝娜,李志勇,唐仕歡(2020)。基於網絡藥理學角度探討清瘟敗毒飲對細胞因子風暴的干預機制。中國中藥雜誌，45(07)，1499-1508。
  40. 陳平安,黃家望,廖燦,袁娉,謝希,陳俊煒(2019)。小柴胡湯對 NTHi 誘導的肺部炎症的影響。中醫藥學報，47(04)，28-32。
  41. 陳益昀,石佔成,石英秀,王艷茹,劉新記(2003)。清瘟敗毒飲加減治療傳染性非典型肺炎 28 例臨床觀察。河北中醫，25(11)，805-806。
  42. 賀煜竣,邢博文,楊凌毓,宋伯騏,張亞蘭,劉未艾,邢博文(2020)。從膜原理論探討達原飲對新型冠狀病毒肺炎早期的治療。世界科學技術─中醫藥現代，1-3。
  43. 黃曉潔,魏剛,張龍(2014)。麻杏石甘湯的藥理作用和臨床應用研究進展。廣東藥學院學報，30(1)，110-114。
  44. 楊敏茹,楊萬軍,張偉東,顧宜,王榮,林瑤(2012)。射干麻黃藥對對支氣管哮喘小鼠模型氣道炎症及外周血 Th1/Th2 的影響。中國藥師，15(03)，309-311。
  45. 劉曉東,云雪林(2020)。基於氣象因素與運氣學說試析新型冠狀病毒肺炎﹙COVID-19﹚相關性。貴州中醫藥大學學報，42(2)，11-15。
  46. 戴有志,黃慧君,劉佳宜(2009)。升降散臨床應用。臺灣中醫臨床醫學雜誌，15(2)，151-155。
被引用次数
  1. 陳朝宗,林家琳,王明仁(2022)。極重度新冠肺炎之中醫會診病例報告。中醫藥研究論叢，25(特刊)，115-136。
  2. 雷才萱,陳凱威,許中華(2022)。中藥淨冠方在COVID-19疫情間之使用感受與滿意度調查。中醫藥雜誌，33(2)，98-110。
  3. 劉虹伶,李聰界,巫孟萱(2021)。探討新型冠狀病毒肺炎指引與常用中醫處方。中醫內科醫學雜誌，19(2)，1-12。
  4. 劉佳祐(2022)。以濕溫論治COVID-19驗案二則。中醫藥研究論叢，25(特刊)，99-103。
  5. 魏任宣,戴毓萱,陳建宏,許中華(2021)。中藥減毒藥方（淨冠方）用於新冠肺炎確診家族追蹤分析。中醫內科醫學雜誌，19(2)，13-24。
  6. 謝明憲,雷才萱,黃建榮,許中華,邱榮鵬(2022)。新冠肺炎及類新冠肺炎者之證型分布及使用淨冠方之滿意。中醫內科醫學雜誌，20(2)，1-11。
  7. 楊東昇,楊士樑,江科郁(2023)。長新冠咳嗽與中醫三焦之臨床新探。中醫藥雜誌，34(2)，23-42。
  8. (2023)。中醫遠距醫療於台灣新冠肺炎之研究。中醫藥研究論叢，26(4)，31-46。
print cancel